Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...

Novo Nordisk on Thursday launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to ...

The Danish drugmaker behind Ozempic topped Pfizer’s bid for Metsera, a move Pfizer describe as "reckless and unprecedented." ...

The Danish pharma was rumored to be a bidder in the process to acquire Metsera earlier this year, which Pfizer ultimately won ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential ...

Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...

Pfizer says Novo Nordisk bid breaks law, calling the $9B Metsera offer an illegal attempt to eliminate a U.S. competitor with antitrust risks.

While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...